Sam Chun Dang Pharm Co Ltd banner
S

Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250

Watchlist Manager
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
Watchlist
Price: 784 000 KRW 6.09% Market Closed
Market Cap: ₩18.4T

Relative Value

The Relative Value of one Sam Chun Dang Pharm Co Ltd stock under the Base Case scenario is hidden KRW. Compared to the current market price of 784 000 KRW, Sam Chun Dang Pharm Co Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Sam Chun Dang Pharm Co Ltd Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

Competitors Multiples
Sam Chun Dang Pharm Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
KR
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
18.2T KRW 82.6 -1 599 1 443.5 7 456.4
US
Eli Lilly and Co
NYSE:LLY
867.4B USD 13.3 42 28.4 30.3
US
Johnson & Johnson
NYSE:JNJ
571.4B USD 6.1 21.3 14.8 18.2
CH
Roche Holding AG
SIX:ROG
250.6B CHF 4.1 19.5 11.5 13
UK
AstraZeneca PLC
LSE:AZN
218.1B GBP 5 28.7 15.9 22.4
CH
Novartis AG
SIX:NOVN
225.3B CHF 5.2 20.8 12.9 16.6
US
Merck & Co Inc
NYSE:MRK
283.3B USD 4.4 15.5 9.6 11.7
IE
Endo International PLC
LSE:0Y5F
240.1B USD 103.6 -82.1 380.1 953.2
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 3.4 10.3 7.6 8.9
US
Pfizer Inc
NYSE:PFE
155.3B USD 2.5 20 7.7 10.2
US
Bristol-Myers Squibb Co
NYSE:BMY
119.5B USD 2.5 17 7.1 8.8
P/E Multiple
Earnings Growth PEG
KR
S
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
Average P/E: 21.7
Negative Multiple: -1 599
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
42
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
21.3
7%
3
CH
Roche Holding AG
SIX:ROG
19.5
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
28.7
26%
1.1
CH
Novartis AG
SIX:NOVN
20.8
14%
1.5
US
Merck & Co Inc
NYSE:MRK
15.5
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -82.1 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.3
1%
10.3
US
Pfizer Inc
NYSE:PFE
20
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
17
16%
1.1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
KR
S
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
Average EV/EBITDA: 176.3
1 443.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
28.4
22%
1.3
US
Johnson & Johnson
NYSE:JNJ
14.8
2%
7.4
CH
Roche Holding AG
SIX:ROG
11.5
6%
1.9
UK
AstraZeneca PLC
LSE:AZN
15.9
13%
1.2
CH
Novartis AG
SIX:NOVN
12.9
5%
2.6
US
Merck & Co Inc
NYSE:MRK
9.6
3%
3.2
IE
E
Endo International PLC
LSE:0Y5F
380.1
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
7.6
1%
7.6
US
Pfizer Inc
NYSE:PFE
7.7
-9%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7.1
-10%
N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett